Get the Stockscreener App
64.30
2.81%
1.76
After Hours:
64.55
0.25
+0.39%
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Zacks Research Issues Negative Outlook for HALO Earnings - Defense World
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN
Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN
Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada
High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance
JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India
Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India
Halozyme Therapeutics Director Sells 5,000 Shares - TradingView
Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock - MarketBeat
Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock - MarketBeat
Los Angeles Capital Management LLC Has $4.42 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics SVP sells $1.26 million in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Michael Labarre Sells Shares of Halozyme The - GuruFocus.com
Halozyme Therapeutics SVP sells shares totaling $1.26 million By Investing.com - Investing.com South Africa
Halozyme Therapeutics SVP sells $1.26 million in stock - Investing.com India
Halozyme Therapeutics SVP sells shares totaling $1.26 million - Investing.com
Halozyme Therapeutics Officer Sells Shares - TradingView
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat
Private Advisor Group LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - Citizentribune
When and How to Catch Halozyme's Crucial TD Cowen Conference Presentation - StockTitan
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Principal Financial Group Inc. - Defense World
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. converted options into 4,747 shares and covered exercise/tax liability with 2,410 shares, increasing direct ownership by 1% to 195,453 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at Benchmark - Defense World
Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole - Quantisnow
SEC Form 4 filed by PRESIDENT AND CEO Torley Helen - Quantisnow
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):